Close Menu

NEW YORK (GenomeWeb) – Luminex announced today it has licensed the Xtreme Chain Reaction nucleic acid amplification technology from XCR Diagnostics.

The XCR technology enables rapid thermal cycling protocols in order to reduce assay turnaround times compared to traditional PCR.

"We look forward to leveraging the benefits that the XCR technology can bring to our future molecular diagnostics portfolio," Luminex President and CEO Homi Shamir said in a statement.

Financial terms for the non-exclusive, worldwide licensing agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.